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Abstract
Epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor-a (PDGFRa) were reported to mediate
entry of HCMV, including HCMV lab strain AD169. AD169 cannot assemble gH/gL/UL128–131, a glycoprotein complex that
is essential for HCMV entry into biologically important epithelial cells, endothelial cells, and monocyte-macrophages. Given
this, it appeared incongruous that EGFR and PDGFRa play widespread roles in HCMV entry. Thus, we investigated whether
PDGFRa and EGFR could promote entry of wild type HCMV strain TR. EGFR did not promote HCMV entry into any cell type.
PDGFRa–transduction of epithelial and endothelial cells and several non-permissive cells markedly enhanced HCMV TR
entry and surprisingly, promoted entry of HCMV mutants lacking gH/gL/UL128–131 into epithelial and endothelial cells.
Entry of HCMV was not blocked by a panel of PDGFRa antibodies or the PDGFR ligand in fibroblasts, epithelial, or
endothelial cells or by shRNA silencing of PDGFRa in epithelial cells. Moreover, HCMV glycoprotein induced cell-cell fusion
was not increased when PDGFRa was expressed in cells. Together these results suggested that HCMV does not interact
directly with PDGFRa. Instead, the enhanced entry produced by PDGFRa resulted from a novel entry pathway involving
clathrin-independent, dynamin-dependent endocytosis of HCMV followed by low pH-independent fusion. When PDGFRa
was expressed in cells, an HCMV lab strain escaped endosomes and tegument proteins reached the nucleus, but without
PDGFRa virions were degraded. By contrast, wild type HCMV uses another pathway to enter epithelial cells involving
macropinocytosis and low pH-dependent fusion, a pathway that lab strains (lacking gH/gL/UL128–131) cannot follow. Thus,
PDGFRa does not act as a receptor for HCMV but increased PDGFRa alters cells, facilitating virus entry by an abnormal
pathway. Given that PDGFRa increased infection of some cells to 90%, PDGFRa may be very useful in overcoming inefficient
HCMV entry (even of lab strains) into the many difficult-to-infect cell types.
Citation: Vanarsdall AL, Wisner TW, Lei H, Kazlauskas A, Johnson DC (2012) PDGF Receptor-a Does Not Promote HCMV Entry into Epithelial and Endothelial Cells
but Increased Quantities Stimulate Entry by an Abnormal Pathway. PLoS Pathog 8(9): e1002905. doi:10.1371/journal.ppat.1002905
Editor: William J. Britt, University of Alabama at Birmingham, United States of America
Received May 18, 2012; Accepted August 1, 2012; Published September 13, 2012
Copyright:  2012 Vanarsdall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work has been supported by NIH grants R01AI081517 and RO1EY018755 to DCJ and RO1EY12509 to AK and a postdoctoral fellowship from the
American Heart Association 09POST2090081 to ALV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: johnsoda@ohsu.edu
Introduction
Human cytomegalovirus (HCMV) is a ubiquitous virus that
establishes lifelong latency or persistence. HCMV normally causes
only mild forms of disease, but in immunocompromised individ-
uals HCMV can cause significant disease [1–3]. AIDS patients
suffer from retinitis, a disease in which HCMV is left unchecked by
reduced host cellular immunity and spreads between retinal
epithelial cells and neurons destroying the retina. Immunosup-
pressed organ transplant patients suffer from HCMV infection of
hepatocytes, lung and gut epithelial cells, and many other cell
types. HCMV infection of placental trophoblasts leads to infection
of the fetus and is associated with infection of microglial cells and
defects in the developing nervous system [4]. Spread of HCMV in
the blood involves infected monocyte-macrophages that can
transmit virus to endothelial cells enabling viral spread into organs
such as the gut, liver, lung, and brain [5]. Thus, in vivo HCMV
infects a wide spectrum of cell types. However, in the laboratory,
most studies are carried out with fibroblasts because the virus
replicates relatively poorly in all other cultured cells.
Entry of HCMV into diverse cell types involves different entry
pathways and viral entry mediators. HCMV binding to cell
surfaces is initiated by interactions with highly charged heparan
sulfate proteoglycans serving to concentrate virions on cell surfaces
and promote other interactions with receptors that are more
restricted in number [6,7]. Entry into human fibroblasts involves
direct fusion with the plasma membrane at neutral pH, delivering
capsids into the cytoplasm [8]. By contrast, entry into epithelial
and endothelial cells involves internalization of virions into
endosomes and low pH-dependent fusion with endosomal
membranes [9]. These two different pathways of entry require
different complexes of HCMV gH/gL proteins.
HCMV assembles a glycoprotein complex composed of gH/gL
decorated with three other proteins: UL128, UL130, and UL131
(gH/gL/UL128–131) that is required for entry into epithelial and
endothelial cells, leuckocytes, and monocytes [9–15]. By contrast,
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[9,11,16]. The assembly of the gH/gL/UL128–131 complex
depends upon expression of all five proteins [12]. Extensive
propagation of HCMV in fibroblasts produced mutations in the
UL128, UL130, and UL131 genes so that laboratory strains, e.g.
AD169, do not infect epithelial and endothelial cells and
monocyte-macrophages because entry is blocked [9,11,17].
HCMV gH/gL also assembles with a third glycoprotein, gO,
forming a disulfide linked trimer [18]. An HCMV TR gO-null
mutant produced virus particles that had highly reduced quantities
of gH/gL and were unable to enter fibroblasts and epithelial and
endothelial cells [19]. Therefore, both gH/gL/UL128–131 and
gH/gL/gO are important for entry of wild type or clinical HCMV
into epithelial and endothelial cells, but only gH/gL/gO is
necessary for entry into fibroblasts.
We used interference to support the hypothesis that gH/gL/gO
and gH/gL/UL128–131 bind saturable receptors. Interference
involves expressing viral receptor-binding glycoproteins in suscep-
tible cells, so that cellular receptors are unavailable for virus entry
[20]. When epithelial cells were transduced with gH/gL/UL128–
131, the cells become resistant to HCMV entry [21]. Expression of
gB, gH/gL or UL128–131 in epithelial cells did not produce
interference. In fibroblasts, expression of gH/gL and gO produced
interference, but expression of gH/gL/UL128–131 or gB did not
interfere [21,22]. These studies supported a working hypothesis
suggesting that HCMV utilizes gH/gL/UL128–131 to interact
with epithelial cell receptors, whereas gH/gL/gO serves to bind
fibroblast receptors (reviewed in [23]). The requirement for
HCMV gH/gL/UL128–131 correlates with entry involving low
pH endosomes.
The HCMV glycoprotein gB is also essential for virus entry into
fibroblasts and likely all cells [24]. Studies of the HSV and Epstein-
Barr virus (EBV) gB homologues have produced evidence that gB
is a fusion-inducing protein that is triggered by gH/gL molecules
to mediate entry fusion [25,26]. Moreover, HSV gB interacts
directly with liposomes, while gH/gL does not [27,28]. However,
there have been reports that HCMV gB can act to bind cellular
receptors. The epidermal growth factor receptor (EGFR) was
described as an HCMV receptor and gB binds EGFR [29].
Activation of EGFR either by HCMV or gB binding produced
cytoplasmic signals that apparently prepared cells for HCMV
entry or early stages of virus replication. The role of EGFR in
HCMV entry was challenged, leading to the conclusions that
EGFR does not play a role in HCMV entry into fibroblasts,
epithelial and endothelial cells and HCMV does not activate
EGFR [30]. The platelet derived growth factor receptor-a
(PDGFRa) was also reported as an HCMV receptor, promoting
entry of both lab and clinical HCMV strains [31]. Again, there
was evidence that HCMV, and specifically gB, caused phosphor-
ylation of PDGFRa and downstream signaling via PDGFRa and
this activation was important for entry or early events in virus
replication. A PDGFRa–neutralizing monoclonal antibody (MAb)
antibody, Gleevec (an inhibitor of PDGFRa kinase activity), and
PDGFRa-specific siRNAs blocked HCMV infection of fibroblasts
[31]. Integrins a2b1, a6b1, and aVb3 have also been reported to
promote HCMV entry into cells and gB binds integrins through a
disintegrin domain [32]. This fits well with evidence that EBV and
Kaposi’s sarcoma herpesvirus utilize integrins in entry [33–35].
Reports that EGFR and PDGFRa can mediate entry of HCMV
lab strain AD169 into fibroblasts, and in some cases into epithelial
and endothelial cells, produced an apparent incongruity in the
literature. AD169 lacks gH/gL/UL128–131 and cannot enter
biologically important epithelial and endothelial cells and mono-
cytes. Thus, it was not clear whether EGFR and PDGFRa were
broadly important in entry of diverse cell types. We reasoned that
there must be distinct pathways and other molecules that interact
with gH/gL/UL128–131 to promote entry into epithelial and
endothelial cells [21,22]. We characterized whether clinical
HCMV strain TR (that expresses gH/gL/UL128–131) relied on
either EGFR or PDGFRa to enter epithelial and endothelial cells.
We found no evidence that EGFR could promote entry of HCMV
TR into any cell type. Transduction of PDGFRa into a variety of
cell types including otherwise highly-resistant cells substantially
increased TR entry. Surprisingly, increased PDGFRa also
markedly promoted entry of HCMV lab strain AD169 and TR
mutants unable to assemble gH/gL/UL128–131. A panel of
PDGFRa-specific antibodies and PDGF (the ligand) did not
inhibit HCMV entry into fibroblasts and epithelial and endothelial
cells and silencing of PDGFRa did not reduce entry into epithelial
cells, supporting the notion that PDGFRa is not normally required
for virus entry into these cell types. Instead, increased expression of
PDGFRa promoted a different pathway of endocytosis and pH-
independent fusion, a pathway that does normally lead to HCMV
entry into these cells.
Results
Expression of PDGFRa and EGFR using adenovirus (Ad)
vectors
To investigate the roles of PDGFRa and EGFR in HCMV
entry into a variety of cells, we constructed non-replicating (E1-)
recombinant adenovirus (Ad) vectors. The PDGFRa or EGFR
genes were coupled to a conditional promoter that was
transactivated by co-transducing cells with a second Ad vector,
Ad-tet-trans, that expresses a tetracycline transactivator protein as
described [12,36]. ARPE-19 retinal epithelial cells were trans-
duced with non-replicating Ad vectors expressing PDGFRa or
Author Summary
Human cytomegalovirus (HCMV) causes substantial mor-
bidity and mortality in immunocompromised patients and
in developing infants. HCMV pathogenesis involves the
capacity to infect many different cell types by multiple
distinct entry pathways. Among the biologically important
cell types infected in vivo are epithelial and endothelial
cells. HCMV specifically requires the viral glycoprotein gH/
gL/UL128–131 to enter these cells. Previous studies
suggested that platelet derived growth factor receptor-a
(PDGFRa) was important for HCMV entry into cells. We
characterized whether PDGFRa was important for HCMV
entry. Increased expression of PDGFRa in cells markedly
augmented entry of wild type and gH/gL/UL128–131-
mutant HCMV into epithelial and endothelial cells, how-
ever, other experiments showed that endogenous PDGFRa
did not normally mediate HCMV entry into these cell types.
Instead, the increased expression of PDGFRa increased
HCMV entry by an abnormal pathway involving clathrin-
independent endocytosis and low pH-independent fusion
with endosomes. HCMV normally enters these cells by
macropinocytosis and low pH-dependent fusion. There-
fore, PDGFRa is not normally an HCMV entry mediator in
these cells, but increased expression of PDGFRa can
promote entry by a different pathway. PDGFRa transduc-
tion of cells may be very useful because many cells are
poorly infected by HCMV and entry represents a major
hurdle.
HCMV Entry into Epithelial Cells
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PDGFRa and EGFR were radiolabeled with [
35S]-methionine-
cysteine and immunoprecipitated. Both PDGFRa and EGFR
were expressed well in these cells (Fig. 1A). It should be pointed
out that ARPE-19 cells normally express PDGFRa [37] but this
expression is significantly lower, compared with that attained
following transduction with this Ad vector. To further characterize
PDGFRa and EGFR expression, ARPE-19 epithelial cells, human
foreskin fibroblasts (HFFs), and human umbilical cord vascular
endothelial (HUVE) cells were transduced with Ad vectors for
24 hr then the cells fixed and stained with PDGFRa- or EGFR-
specific antibodies in immunofluorescence experiments. For each
cell type, there was significant expression of PDGFRa and EGFR
in the vast majority of cells (Fig. 1B).
Transduction of epithelial and endothelial cells with
PDGFRa, but not EGFR, increases HCMV infection
To determine whether PDGFRa or EGFR would increase
HCMV infection of ARPE-19 epithelial and HUVE cells, cells
were transduced with Ad vectors to express PDGFRa or EGFR
then incubated with HCMV clinical strain TR at 10 IU/cell. The
percentage of cells that HCMV could enter was evaluated by
assaying for the expression of the HCMV immediate early protein
IE-86 by immunofluorescence. This measures productive entry,
leading to infection of the cells, which is of utmost importance in
these studies. ARPE-19 cells transduced with the control Ad vector
(Ad-tet-trans) displayed 33% IE-86+ cells (Fig. 2A). ARPE-19 cells
transduced to express EGFR were infected at similar levels. By
contrast, ARPE-19 cells transduced with PDGFRa were much
more extensively infected by HCMV, with 97% of the cells IE-86+
(Fig. 2A). Similar results were observed with HUVE cells, where
24% of the cells transduced with the control Ad-tet-trans vector
were infected and there was no increase following transduction
with EGFR (Fig. 2B). However, 64% of the HUVE cells
transduced with PDGFRa were infected with HCMV (Fig. 2B).
Human foreskin fibroblasts (HFF) cells were very efficiently
infected with HCMV TR, so that cells transduced with the
control Ad-tet-trans exhibited 98% IE-86+ cells using only 1 IU/
cell, and this high level of infection was not changed when cells
were transduced with PDGFRa or EGFR (Fig. 2C).
We also tested whether PDGFRa could enhance HCMV entry
into non-permissive, non-human cells. HCMV infected only a
small percentage of owl monkey kidney (OMK) cells and rat
retinal pigmented epithelial (rat-RPE) cells transduced with the
control Ad vector (Fig. 2D,E). That this defect in IE-86 expression
involved defects in entry was previously demonstrated using
polyethylene glycol (PEG), a chemical fusogenic agent that
promoted IE-86 expression in the majority of cells [38]. Following
transduction with PDGFRa, the numbers of IE-86+ OMK and
rat-RPE cells was increased by 100 or 60-fold, respectively
(Fig. 2D, E). We concluded that expression of PDGFRa can
dramatically increase HCMV infection of human and non-human
cells.
PDFGRa enhances entry of HCMV unable to assemble
gH/gL/UL128–131
We previously showed (using PEG) that HCMV mutants unable
to assemble the five-protein complex gH/gL/UL128–131 are
defective for entry into epithelial and endothelial cells [9]. As in
the previous studies, AD169 and a TR mutant lacking the UL131
gene (TRD131), which can not assemble gH/gL/UL128–131,
infected ARPE-19 cells transduced with the control Ad-tet-trans
poorly, i.e. less than 1% of the cells expressed IE-86 (Fig. 3A).
Figure 1. Characterization of Ad vectors expressing human
PDGFRa and EGFR. (A) ARPE-19 epithelial cells were transduced with
Ad-tet-trans alone (100 PFU/cell) or Ad-PDGFRa and Ad-tet-trans
(50 PFU/cell of each) or Ad-EGFR and Ad-tet-trans (50 PFU/cell of each)
for 24 hr then radiolabeled with [
35S]-methionine-cysteine for 4 hr. The
cells were lysed and the PDGFRa or EGFR proteins immunoprecipitated
with a goat polyclonal antibody AF-307-NA or mouse MAb LA1,
respectively. The precipitated proteins were analyzed by SDS-PAGE.
Molecular weight markers are indicated on the left. IP refers to the
protein immunoprecipitated. (B) ARPE-19 epithelial, human foreskin
fibroblasts (HFF), and human endothelial cells (HUVECs) were trans-
duced with Ad vectors expressing tet-trans, PDGFRa, or EGFR as
described above, incubated for 24 hr then fixed and stained with the
PDGFRa-specific antibody AF-307-NA or EGFR-specific antibody LA-1
followed by a FITC-conjugated donkey anti-goat (Molecular Probes) or a
Dylight 594-congugated goat anti-mouse secondary antibody.
doi:10.1371/journal.ppat.1002905.g001
HCMV Entry into Epithelial Cells
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the cells highly permissive for infection by both AD169 and
TRD131, 97 and 98% of the cells were positive for IE-86,
respectively (Fig. 3A). Similar effects were observed with TRD4
[9], a mutant lacking all of UL128, UL130 and UL131 (not
shown). In addition, expression of PDGFRa in HUVE cells
increased infection of AD169 and TRD131 by 100 and 137 fold,
respectively (Fig. 3B). We concluded that increased expression of
PDGFRa can greatly increase entry of both wild type HCMV and
mutants lacking gH/gL/UL128–131 into epithelial and endothe-
lial cells.
Expression of PDGFRa overcomes gH/gL/UL128–131-
mediated interference in epithelial cells
Previously, expression of gH/gL/UL128–131 in ARPE-19
epithelial cells produced interference, consistent with our hypoth-
esis that gH/gL/UL128–131 binds epithelial-specific receptors
that are required for entry [21,22]. Given observations that gH/
gL/UL128–131 was not required for HCMV entry into ARPE-19
cells expressing PDGFRa, we tested whether gH/gL/UL128–131
would produce interference in ARPE-19 cells that also express
PDGFRa. HCMV infected 37% of ARPE-19 cells transduced
with the control Ad-tet-trans vector (Fig. 4A, E), whereas 90% of
cells expressing PDGFRa were infected (Fig. 4B, E). There were
no detectable HCMV infected cells expressing gH/gL/UL128–
131, related to interference (Fig. 4C, E). However, ARPE-19 cells
expressing both PDGFRa and gH/gL/UL128–131 were effi-
ciently infected by HCMV, 78% of the cells expressed IE-86 (Fig. 4
D, E). Therefore, expression of PDGFRa in ARPE-19 overcomes
gH/gL/UL128–131-mediated interference. Coupled with obser-
vations in the last section, this suggested that gH/gL/UL128–131
does not interact with PDGFRa and PDGFRa produces an
alternate pathway of entry.
The PDGF ligand and PDGFRa-specific antibodies do not
reduce HCMV infection of epithelial, endothelial, and
fibroblasts cells and silencing of PDGFRa in epithelial
cells did not reduce entry
To further address whether PDGFRa plays a role in HCMV
entry into normal cells, we attempted to block PDGFRa with
antibodies and the PDGF ligand. Previously, it was reported that
10 ng/ml of the PDGFR ligand, PDGF-AA, inhibited HCMV
infection of human embryonic lung fibroblasts [31]. Normal
ARPE-19, HUVE cells, or HFFs were treated with various doses
of PDGF-AA then infected with HCMV TR and assayed for
HCMV IE-86 expression after 24 hr. There was no observed
inhibition of HCMV entry into any of these cell types even at
20 ng/ml of PDGF-AA (Fig. 5A). To test whether PDGFRa-
specific antibodies would block HCMV infection, ARPE-19 cells
were pre-incubated with a panel of five different PDGFRa-specific
antibodies then infected with HCMV TR and assayed for IE-86
expression after 24 hr. None of the PDGFRa-specific antibodies
tested, including PDGFRa-neutralizing antibodies AF-307-NA
and MAb 35248, reduced HCMV entry into ARPE-19 cells
(Fig. 5B), HUVE cells (Fig. 5C), or fibroblasts (Fig. 5D).
To further investigate the role of PDGFRa in the normal route
of entry of HCMV into epithelial cells, we characterized an
Figure 2. Expression of PDGFRa enhances entry of HCMV TR
into epithelial and endothelial cells. A) Human epithelial cells
(ARPE-19), B) human endothelial cells (HUVECs), C) human foreskin
fibroblasts (HFF), D) owl monkey kidney cells (OMK), and E) rat retinal
epithelial cells (Rat-RPE) were transduced with Ad vectors expressing
tet-trans, PDGFRa, or EGFR using 50 PFU/cell for each Ad vector for
24 hr. The cells were infected with HCMV TR using 10 IU/cell and 1 IU/
cell for HFF cells then fixed, permeabilized, and stained for HCMV IE-86
immediate early protein. The percent infected cells was calculated by
counting the number of IE-86+ cells in three fields from three separate
wells involving two separate experiments, comparing to the total
number of cells in each field then averaging the numbers. Standard
deviations are indicated.
doi:10.1371/journal.ppat.1002905.g002
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with a retrovirus vector expressing an shRNA to knockdown
endogenous levels of PDGFRa [37]. Western blot analysis showed
80% reduction in PDGFRa expression in the ARPE-19 knockdown
cells compared to normal ARPE-19 cells (Fig. 6A), as reported
previously [37]. An ARPE-19 cell line that overexpresses PDGFRa
followingtransduction witha retrovirusvector(ARPE-19a) wasalso
characterized and shown to express 10–30-fold higher levels
PDGFRa compared with normal APRE-19 cells (Fig. 6A). Note
that we were unable to detect PDGFRa following radiolabeling of
ARPE-19 cells in Fig. 1A. This difference relates to increased
sensitivity of the Western blots. The ARPE-19a and ARPE-19 KD
cells were tested for HCMV infection. Normal ARPE-19 cells
displayed 39% IE-86+ cells 24 hr after HCMV infection and 38%
of the ARPE-19 KD cells were infected. The ARPE-19a cells
exhibited markedly increased numbers of IE-86+ cells (95%) as in
previous experiments involving ARPE-19 cells transduced with Ad
vectors. Together with the results of experiments involving
PDGFRa-specific antibodies and the PDGFR ligand, these
silencing experiments supported our conclusion that endogenous
PDGFRa is not important for HCMV entry into cells.
Gleevec inhibits HCMV IE-86 expression into ARPE-19
cells, but also blocks HSV IE protein expression
In the previous report, the tyrosine kinase inhibitor imantinib
methanesulfonate (Gleevec) substantially inhibited PDGFRa-medi-
ated phosphorylation of Akt and HCMV IE expression in human
embryonic lung (HEL) cells and U87 glioblastoma cells [31]. Thus,
we pretreated cells with various doses of Gleevec prior to infecting
the cells with HCMV TR in the presence of Gleevec. There was a
50–60% inhibition of the numbers HCMV IE-86+ cells when cells
were treated with 25 and 50 nM Gleevec and 90–100% inhibition
with 75 and 100 nM Gleevec (Fig. 7A). To determine whether this
effect was specific for HCMV, Gleevec-treated ARPE-19 cells were
infected with HSV-1. Gleevec at 50 and 75 nM concentrations
produced ,60% inhibition of the number of HSV immediate early
ICP4 protein expressing cells and 100 nM Gleevec reduced HSV
IE expressing cells to ,1% (Fig. 7B). Because Gleevec inhibited
both HSV and HCMV IE expression, Gleevec does not specifically
affect HCMV entry and more likely has general effects on cells,
likely reducing viral gene expression.
PDGFRa expression does not increase HCMV
glycoprotein-induced cell-cell fusion
One important approach toward understanding virus entry has
involved the delineation of viral glycoproteins and cellular proteins
that promote cell-cell fusion. Studies with HSV showed that
glycoproteins gB, gD, and gH/gL were all required both for cell-
cell fusion and virus entry [39–45]. Importantly, cells lacking HSV
receptors (HVEM and nectin-1) do not fuse and when transfected
with HVEM or nectin-1 the cells become permissive for fusion
[46–49]. We previously described HCMV TR gB and gH/gL as
the minimal fusion machinery and observed a strong correlation
between HCMV entry into human and non-human cells and
whether the cells could fuse when HCMV gB and gH/gL were
expressed in the cells [38]. As in the previous studies, a majority
(60%) of ARPE-19 effector cells transduced with gB and gH/gL
fused after mixing with ARPE-19 target cells transduced with the
control Ad vector Ad-tet-trans (Fig. 8A). There was no significant
increase in cell-cell fusion when ARPE-19 effector cells expressing
gB and gH/gL were mixed with ARPE-19 target cells expressing
PDGFRa (Fig. 8B). Previously, we reported that HeLa cells and
rat-RPE cells did not fuse when the cells were transduced with
HCMV gB and gH/gL and HCMV would not enter these cells
[38]. To determine whether expression of PDGFRa promoted
fusion of these cells, HeLa or rat-RPE effector cells expressing
HCMV gB and gH/gL were mixed with HeLa or rat-RPE cells
expressing PDGFRa. Under these conditions, no fusion was
Figure 3. HCMV entry into PDGFRa expressing epithelial and endothelial does not require gH/gL/UL128–131 complexes. A) ARPE-19
epithelial cells or B) HUVECs were transduced with Ad-tet-trans or Ad-PDGFRa and Ad-tet-trans for 24 hr. The cells were then incubated with either
HCMV lab strain AD169 or HCMV TR mutant virus TRD131 at 10 IU/cell for an additional 24 hr, then fixed, permeabilized, and assayed for HCMV
infection by staining cells for the HCMV IE-86 early antigen. As in Fig. 2, the percent infected cells was calculated by counting IE-86 positive cells in
three separate wells involving two experiments and the average number of IE-86+ cells indicated in the lower right of each panel.
doi:10.1371/journal.ppat.1002905.g003
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and to establish a baseline level of glycoprotein-mediated fusion in
these cells, HeLa and rat-RPE effector cells were transduced with
Ad vectors expressing HSV-1 gB, gD and gH/gL then mixed with
HeLa or rat-RPE target cells expressing the HSV-1 entry receptor
nectin-1. Under these conditions, 40% of the HeLa cells fused
(Fig. 8D), while 44% of rat RPE cells fused (Fig. 8F). We
concluded that PDGFRa does not promote cell-cell fusion,
supporting the conclusions that the HCMV fusion glycoproteins
do not interact directly with PDGFRa and that PDGFRa does not
act as a HCMV receptor.
HCMV entry into ARPE-19 cells transduced with PDGFRa
involves a different pathway compared with normal
ARPE-19 cells
Previously, we reported that wild HCMV TR enters epithelial
and endothelial cells by endocytic internalization and low pH-
dependent fusion with endosomes [9]. Endocytosis was inferred
from rapid internalization into epithelial cells and the requirement
for low pH. Here, we characterized the pathways of entry into
normal and PDGFRa-transduced ARPE-19 cells in more detail.
Treating cells with NH4Cl (50 mM) raises endosomal pH, without
causing cytotoxicity, and inhibited HCMV TR entry into normal
ARPE-19 cells, but did not block entry into PDGFRa-transduced
ARPE-19 cells (Fig. 9A). The small molecule inhibitor dynasore
inhibits dynamin-2 that is crucial for endocytic vesicle formation in
clathrin- and caveolin-mediated endocytosis [50], as well as more
poorly understood clathrin- and caveolin-independent endocytic
pathways [50,51]. HCMV entry into both normal and PDGFRa-
transduced ARPE-19 cells was reduced 88% or more by dynasore
(Fig. 9A). Chlorpromazine which inhibits clathrin-mediated
endocytosis [52], did not significantly inhibit HCMV entry into
either normal or PDGFRa-transduced ARPE-19 cells. The
amiloride analog, 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) inhib-
its the Na+/H+ exchanger and specifically blocks macropinocy-
tosis [53]. EIPA significantly inhibited HCMV entry into ARPE-
19 cells, but had minimal effects on virus entry into ARPE-19 cells
transduced with PDGFRa (Fig. 9A). Rottlerin, another inhibitor of
macropinocytosis [54] had no effect on entry into PDGFRa-
transduced ARPE-19 cells, but reduced entry into normal ARPE-
19 cells.
Transferrin receptor (TfR) is normally taken up by clathrin-
mediated endocytosis [55]. To measure whether PDGFRa
transduction of cells increased TfR uptake, normal ARPE-19 or
ARPE-19a (with increased PDGFRa) were incubated with
fluorescent transferrin for 30 min at 37uC then cells briefly treated
with pH 3.0 citrate buffer to remove cell surface transferrin and
the cells imaged. There were no differences in the uptake of
transferrin into cells in which PDGFRa was increased (Fig. 9B).
When these cells were treated with chlorpromazine, fluorescent
transferrin uptake into the cytoplasm was dramatically reduced
(Fig. 9B). This experiment served as a positive control for the
experiments in Fig. 9A, supporting the conclusion that HCMV
does not enter normal or PDGFRa-transduced ARPE-19 cells by
clathrin-mediated endocytosis.
We also measured whether PDGFRa increased the internali-
zation of HCMV particles and delivery of a viral tegument protein
to the nucleus. The HCMV recombinant, UL32-EGFP-HCMV,
expresses a fluorescent tegument protein pp150-EGFP that
produces fluorescent virons, as well as tegument puncta in the
cytoplasm and nucleus following infection of fibroblasts [56]. It is
important to note that UL32-EGFP-HCMV was derived from
strain TB40, which was extensively passaged on fibroblasts and
does not infect endothelial and epithelial cells well. Related to this,
we showed that UL32-EGFP-HCMV was highly defective in
producing IE-86 in ARPE-19 cells, compared with HCMV TR or
TB40/E (not shown). Based on previous studies [57], it is highly
likely that UL32-EGFP-HCMV cannot assemble gH/gL/UL128–
131 explaining the inability to infect epithelial cells. UL32-EGFP-
HCMV particles from cell culture supernatants were applied to
normal or PDGFRa-transduced ARPE-19 cells for 1 hr at 37uC,
then the cells washed and incubated for 2–24 hr at 37uC before
imaging. After 2 and 4 hr, there were no obvious differences in the
uptake of fluorescent particles into the cytoplasm of normal or
PDGFRa-transduced cells (Fig. 9C). At 8 hr there was still no
clear discernable differences in the number of particles (not
shown). However, after 12, 16, and 24 hr, PDGFRa-transduced
ARPE-19 cells exhibited substantial quantities of pp150-GFP
puncta in the cytoplasm and in the nucleus. By contrast, there
were few remaining pp150-GFP puncta in normal ARPE-19 cells
after 12,16, and 24 hr and no fluorescent puncta in the nucleus
(Fig. 9C.) We also looked at 24 hr post-infection to determine
Figure 4. PDGFRa overcomes gH/gL/UL128–131 mediated
interference in ARPE-19 epithelial cells. ARPE-19 epithelial cells
were transduced with A) Ad-tet-trans alone, B) Ad-PDGFRa and Ad-tet-
trans, C) Ad vectors expressing all of gH, gL, UL128, UL130 and UL131
and Ad-tet-trans, D) Ad- PDGFRa and vectors expressing gH, gL, UL128,
UL130, UL131 and Ad-tet-trans for 24 hr. The cells were incubated with
HCMV TR using 10 IU/cell for a further 24 hr, then the cells cells fixed,
permeabilized, and stained for HCMV IE-86 early antigen. E) The percent
of HCMV infected cells was quantified as described in Fig. 2. Error bars
indicate the standard deviation.
doi:10.1371/journal.ppat.1002905.g004
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Whereas the internalization of particles in PDGFRa-transduced
cells led to expression of IE-86, the very few pp150-GFP puncta
that remained exclusively in the cytoplasm in normal ARPE-19
cells did not lead to expression of IE-86 (Fig. 9C). These results
suggested that similar numbers of HCMV particles were taken up
by endocytosis into both normal and PDGFRa-transduced cells.
In PDGFRa-transduced cells, HCMV particles entered the
cytoplasm and reached the nucleus, whereas in normal ARPE-
19 cells, particles were degraded.
Together, the results in this section demonstrated that HCMV
can be internalized into ARPE-19 cells by at least two endocytic
pathways. Wild type HCMV particles containing gH/gL/UL128–
131 can be internalized by macropinocytosis and can then fuse
with endosomes requiring low pH. However, HCMV with or
without gH/gL/UL128–131 can also be internalized by dynamin-
dependent, clathrin-independent endocytosis. When cells are
transduced to increase PDGFRa expression, this pathway leads
to low pH-independent fusion and productive infection, whether
virus particles possess gH/gL/UL128–131 or not. However,
without increased PDGFRa expression, HCMV particles do not
fuse with endosomes and are degraded, likely in lysosomes,
disappearing from the cytoplasm as observed with UL32-EGFP-
HCMV.
Discussion
HCMV lab strains such as AD169 cannot assemble gH/gL/
UL128–131 and cannot enter epithelial and endothelial cells.
EGFR and PDGFRa were reported to mediate entry of HCMV
AD169 into human fibroblasts, and for PDGFRa, entry into
endothelial and epithelial cells. We reasoned that EGFR and
Figure 5. The PDGF ligand (PDGF-AA) and PDGFRa antibodies do not reduce HCMV infection of epithelial, endothelial cells, and
fibroblasts. (A) ARPE-19, HUVECs, or foreskin fibroblasts (HFF) were pre-treated with PDGF-AA ligand at various concentrations at 46C for 30 min
then HCMV TR (10 IU/cell, 1 IU/cell for fibroblasts) was added to the cells in the presence of PDGF-AA at 46C for an additional 30 min. The cells were
shifted to 376C for 4 hr then washed to remove the virus inoculum and fresh growth media containing the same concentration of PDGF-AA was
added. After an additional 24 hr, the cells were fixed, permeabilized, and stained for HCMV IE-86. Relative entry was characterized by comparing the
number of IE-86 positive cells in three separate fields with other dishes of cells not treated with PDGFR-AA. Error bars indicate the standard deviation.
B) ARPE-19 cells, C) HUVE cells or D) human foreskin fibroblasts were incubated with various doses of PDGFRa-specific antibodies for 1 hr at 4uC then
incubated with HCMV TR (10 IU/cell, 1 PFU/cell for fibroblasts) in the presence of these antibodies for an additional 1 hr at 4uC. The cells were then
shifted to 37uC for 4 hr, washed to remove the virus inoculum then incubated at 37uC for 24 hr in the presence of antibodies. The cells were then
stained for IE-86. Relative entry refers to the frequency of IE-86 positive cells compared to cells not treated with antibodies and was determined from
at least three separate fields. Error bars indicate the standard deviation.
doi:10.1371/journal.ppat.1002905.g005
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wild type HCMV into epithelial and endothelial cells because this
process requires gH/gL/UL128–131 and AD169 does not
assemble this glycoprotein complex. Moreover, our interference
data suggested that gH/gL/UL128–131 binds saturable receptors
specifically expressed by epithelial cells and not by fibroblasts
[21,22]. EGFR and PDGFRa were increased in a variety of cells
using Ad vectors. Ad transduction of EGFR did not increase entry
of wild type HCMV TR into any cell type tested, fibroblasts,
epithelial and endothelial cells. Moreover, EGFR-specific anti-
bodies in the present studies (not shown) and our published studies
did not inhibit HCMV cell-cell fusion and entry into any cell type
[38]. Our conclusion that EGFR is not important for HCMV
entry into fibroblasts, epithelial, and endothelial cells is similar to
that in a previous report [30]. By contrast, Ad transduction of
PDGFRa substantially enhanced entry of HCMV TR into human
epithelial and endothelial cells, 97% of PDGFRa–transduced
ARPE-19 cells were infected, compared with 33% of normal
ARPE-19 cells. Expression of PDGFRa also substantially
enhanced HCMV entry into owl monkey kidney cells and rat
epithelial cells, cells that HCMV cannot normally infect. By
contrast, entry of HSV-1 into rat epithelial cells was not enhanced
by PDGFRa (not shown). These initial results suggested that
PDGFRa was functioning as a bona fide entry receptor for
HCMV in epithelial and endothelial cells.
However subsequent studies of the role of PDGFRa in HCMV
entry quickly cast a different light on the question of whether this
protein normally functions to promote HCMV entry into these
cells. Surprisingly, expression of PDGFRa in epithelial and
endothelial cells promoted high-level entry of HCMV mutants
unable to assemble gH/gL/UL128–131, ie. a TR UL131- mutant
entered 0.5% of normal ARPE-19 cells but 98% of PDGFRa-
transduced ARPE-19 cells. This suggested that gH/gL/UL128–
131 was not important for binding to PDGFRa or for HCMV to
enter PDGFRa-transduced cells and contrasted with observations
that gH/gL/UL128–131 is normally vital for entry into these cells
[9]. Moreover, we observed no interference when gH/gL/
UL128–131 was expressed in PDGFRa–expressing APRE-19
cells, in contrast to previous observations with normal ARPE-19
cells [21,22]. Together, these observations argued that PDGFRa
Figure 6. Reduction in expression of PDGFRa in ARPE-19
epithelial cells does not reduce HCMV infection. A) ARPE-19 cells,
ARPE-19 cells transduced with a retrovirus expressing an shRNA
targeting PDGFRa (ARPE-19 KD), or ARPE-19 cells transduced with a
retrovirus causing overexpression of PDGFRa (ARPE-19a) were analyzed
by staining western blots with a PDGFRa–specific polyclonal antibody.
As a loading control, the same membrane was also probed for the
cellular protein, b-actin with the mouse MAb AC-15. Note that the same
gel was used to analyze PDGFRa in all three cell types, but a much
stronger PDGFRa signal was expected for ARPE-19a cells and, thus, we
separated the lanes in the figure. B) ARPE-19, ARPE-19 KD, and ARPE-
19a cells were incubated with HCMV TR using 10 IU/cell for 24 hr then
the cells were fixed, permeabilized, and stained for HCMV IE-86. The
percent cells infected was derived by counting IE-86+ cells in at least
three separate fields. Error bars represent the standard deviation.
doi:10.1371/journal.ppat.1002905.g006
Figure 7. Gleevec inhibits both HCMV and HSV immediate
early protein expression. Normal ARPE-19 cells were treated with
various concentrations of Gleevec for 1 hr at 376C then incubated with:
A) HCMV TR using 10 IU/cell or B) HSV-1 using 10 PFU/cell in the
presence of Gleevec for 4 hr at 376C. The cells were washed to remove
the virus inoculum then incubated for an additional 24 hr in growth
media containing the same concentration of Gleevec. HCMV-infected
cells were stained for IE-86 and HSV-infected cells were stained for
immediate early protein ICP4. The percent infected cells was calculated
by determining the percent IE-86+ or ICP4+ cells and comparing to the
number of IE-86+ or ICP4+ cells observed when a different set of cells
were treated with Gleevec after the virus inoculum was removed (at
4 hr post-infection). The numbers represent the average from at least
three separate fields. Error bars represent the standard deviation.
doi:10.1371/journal.ppat.1002905.g007
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epithelial cells that requires gH/gL/UL128–131.
Additional evidence against PDGFRa acting as an important
entry mediator in these cells came from studies involving
antibodies and the PDGF ligand. Soroceanu et al. reported that
the PDGF ligand and a PDGFRa–neutralizing MAb both
inhibited HCMV entry into fibroblasts [31]. However, here, a
panel of five different PDGFRa-specific antibodies, including two
that neutralize PDGFRa, did not block HCMV entry into any of
three cell types, fibroblasts, epithelial and endothelial cells, and the
PDGF ligand had no effect on entry. Moreover, HCMV entered
ARPE-19 cells transduced with PDGFRa–specific shRNA (reduc-
ing PDGFRa expression by <80%) to the same extent as with
normal ARPE-19 cells. The antibody, PDGF ligand, and shRNA
results all suggested that HCMV does not depend upon
endogenous PDGFRa during entry into ARPE-19. Coupled with
observations that gH/gL/UL128–131 is not necessary for entry
into PDGFRa transduced cells, there must be other entry
mediators that depend upon gH/gL/UL128–131. It was also
reported that Gleevec, an inhibitor of PDGFRa–mediated
signaling, inhibited HCMV entry into fibroblasts [31]. We found
that Gleevec inhibited expression of both HCMV and HSV
immediate early protein expression. Gleevec was developed as an
inhibitor of the Abl tyrosine kinase and, thus, inhibits more than
just PDGFRa. Therefore, it was not surprising that Gleevec
caused more generalized effects in cells and the reduction of early
gene expression was not specific to HCMV.
Further support for the notion that HCMV does not interact
directly with PDGFRa came from cell-cell fusion studies.
Increased PDGFRa did not increase cell-cell fusion involving
ARPE-19 cells or HeLa and rat-RPE cells, cells that lack HCMV
entry mediators and do not normally fuse [38], yet HeLa and rat-
RPE cells fused with HSV glycoproteins. Previous studies of HSV
and EBV cell-cell fusion demonstrated that virus receptors or entry
mediators are absolutely required for cell-cell fusion [34,46–
49,58]. Although unlikely, it is possible that PDGFRa interacts
with other viral proteins, not gB or gH/gL, to promote fusion or
entry.
The pathway of entry of HCMV into PDGFRa transduced cells
differed from that used by wild type HCMV to enter normal cells
(depicted in Fig. 10). Wild type HCMV TR enters normal ARPE-
19 cells by macropinocytosis (blocked by EIPA and rottlerin) and
the low pH of endosomes (raised by NH4Cl) was required for entry
fusion, i.e. access to the cytoplasm and induction of IE-86 (Fig. 10,
right side). Dynasore specifically inhibits dynamin-mediated
membrane scission and can block both endocytosis and macro-
pinocytosis [59] and blocked entry of TR into normal ARPE-19
cells. Importantly, this pathway requires gH/gL/UL128–131, so
that AD169 and TR mutants lacking UL128–131 cannot enter by
this pathway. The left side of Fig. 10 depicts HCMV strains
AD169 and TB40 (UL32-EGFP-HCMV), and likely TR, which
can be internalized by another endocytic pathway requiring
dynamin (inhibited by dynasore), but not requiring clathrin (not
inhibited by chlorpromazine) and not involving macropinocytosis
(not inhibited by EIPA and rottlerin) (Fig. 10, left). This pathway is
apparently clathrin-independent endocytosis and does not require
gH/gL/UL128–131, as evidenced by uptake of UL32-EGFP-
HCMV and IE-86 expression by AD169. When PDGFRa
expression is increased in cells, HCMV particles present in
endosomes can fuse with endosomes, enter the cytoplasm, and
allow viral DNA and tegument proteins to reach the nucleus. This
pathway does not require low pH for fusion. Without increased
expression of PDGFRa, UL32-EGFP-HCMV (TB40) and likely
AD169 are unable to fuse with endosomes and degraded over
time, apparently in lysosomes. This was supported by reduced
numbers of pp150-EGFP fluorescent particles or puncta after
12 hr in normal ARPE-19 cells, compared with PDGFRa-
expressing ARPE-19 cells and appearance of pp150-GFP in the
nucleus.
It seems likely that endocytosis, macropinocytosis, and other
types of internalization of virus particles occur simultaneously in
most cells, but the majority of these processes do not result in
productive entry, i.e. arrival in the cytoplasm, transport to nuclear
pores and viral gene expression. For example, HSV particles that
were applied to cells expressing gD (that interferes with entry) were
internalized, remained in cytoplasmic vesicles, and were eventually
degraded in lysosomes [60]. This was similar to the apparent fate
of UL32-EGFP-HCMV particles in normal ARPE-19 cells.
HCMV requires gH/gL/UL128–131 to access or exit from the
endosomes engendered by macropinocytosis in normal ARPE-19
cells. However, virus particles lacking gH/gL/UL128–131 can
access the alternate endocytic pathway when there is increased
Figure 8. PDGFRa expression does not increase HCMV gB and
gH/gL-induced cell-cell fusion. A, B, C, and E) Effector cells were
established by transducing A&B ) ARPE-19 cells, C) HeLa cells or E) rat-
RPE cells with Ad vectors expressing HCMV gH, gL and gB and Ad-tet-
trans. Target cells were established by transducing other cells of the
same kind with A) Ad-tet-trans vector alone or B, C, and E) Ad-PDGFRa
and Ad-tet-trans. D) HeLa effector cells were transduced with Ad
vectors expressing HSV glycoproteins gB, gH, gL, and gD and HeLa
target cells established by transducing cells with an Ad vector
expressing nectin-1. F) rat-RPE effector cells were established by
transduction with Ad vectors expressing HSV glycoproteins gB, gH, gL,
and gD and rat-RPE target cells were established by transducing cells
with an Ad vector expressing nectin-1. In every case, effector cells and
target cells were trypsinized then replated in equal numbers in small
dishes for 24–36 hr. To assess cell-cell fusion, cell monolayers were fixed
and stained with syto-green dye (Invitrogen) and fusion was quantified
from micrographic images by counting the number of nuclei involved
in syncytia formation divided by the total number of nuclei. The percent
of fused cells was calculated by counting fused cells versus unfused
cells in 3 fields from 3 separate dishes from 2 experiments and involving
over 500 cells and standard deviations indicated.
doi:10.1371/journal.ppat.1002905.g008
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membranes without low pH. It seems likely that increased
PDGFRa signaling is responsible for these cytoplasmic steps.
PDGFRa signaling involves dimerization, autophosphorylation,
activation of tyrosine kinase activity, docking of other proteins and
activation of a panel of partners including phospholipase C-c, ras-
MAP kinase, phosphatidylinositol 3-kinase (PI3K), and members
of the src family of tyrosine kinases (reviewed in [61]). Important
for our studies, PDGFRa activation affects both dynamin-2 that
interacts with activated PDGFRa at the advancing edges of motile
glioblastoma cells [62] and cortical actin cytoskeleton leading to
marked membrane ruffling [63]. Thus, it is probable that
PDGFRa increases HCMV entry through rearrangements of
actin and, perhaps, dynamin-2 activity.
In summary, our studies have three important implications.
First, we documented that both EGFR and PDGFRa are not
important HCMV entry mediators in epithelial, endothelial, and
fibroblast cells. These results help explain the incongruity in the
literature involving the use of EGFR and PDGFRa by AD169 that
lacks gH/gL/UL128–131. Coupled with our interference studies
[21,22], our results suggest other cellular molecules. However,
importantly, it is very possible that HCMV enters other cell types,
cells not studied here, involving these PDGFRa–mediated
changes.
Second, our studies describe a very novel mechanism of action
of PDGFRa that promotes entry of HCMV with or without gH/
gL/UL128–131 by an abnormal pathway into both biologically
relevant human epithelial and endothelial cells and several highly
resistant cell types. We provided evidence that the HCMV entry
machinery does not bind PDGFRa, instead PDGFRa alters
endocytic machinery, allowing virus to escape endosomes that
would otherwise be a dead end. There are extensive examples of
herpesvirus entry into cells by different mechanisms, but none (that
we know of) involving changes brought about in endosomal
pathways related to expression of a signaling molecule that
produces an entirely different pathway of entry. One could argue
that the levels of PDGFRa that we expressed in these cells were
not physiologically relevant. However, we observed huge increases
Figure 9. The pathway of HCMV entry into PDGFRa expressing epithelial cells is different from that involving normal ARPE-19 cells.
A) ARPE-19 cells were transduced with Ad-tet-trans alone (Normal) or Ad-PDGFRa and Ad-tet-trans (PDGFRa expressing) for 24 hr at 376C. The cells
were incubated with 0.2% DMSO (No drug), 50 mM ammonium chloride (NH4Cl), 150 mM dynasore (Dyna), 30 mM chlorpromazine (Cpz), 30 mM
Rottlerin, or 75 mM EIPA for 1 hr at 376C then HCMV TR (10 IU/cell) was added for an additional 4 hr in the presence of drugs. The cells were then
washed to remove the virus inoculum then incubated in media containing 10% FBS and the same concentration of drug for 24 hr at 376C. The
relative level of HCMV infection was measured by comparing the number of IE-86 positive cells in drug-treated cells with cells treated with 0.2%
DMSO. The bars represent the averages from three separate wells from one experiment with standard deviations shown. Other experiments
produced very similar data. B) ARPE-19 or ARPE-19a cells were treated with either 0.2% DMSO or with 30 mM chlorpromazine (Cpz) for 1 h at 376C
then incubated with media containing Alexa-fluor-488 transferrin and DMSO or chlorpromazine for 30 min at 376C. The cells were placed on ice,
washed briefly with citrate buffer, pH 3.0 to remove cell surface transferrin, fixed, the nuclei stained with DAPI, then analyzed by fluorescent
microscopy. C) ARPE-19 or ARPE-19a cells seeded on glass coverslips were incubated with UL32-EGFP-HCMV using 10 IU/cell for 1 hr at 37uC then the
cells washed and incubated for an additional 2, 4, 12, 16 hr in growth media before the cells were fixed, nuclei counterstained with DAPI, and cells
analyzed by fluorescence microscopy. Cells incubated for 24 hr were fixed, permeabilized, and stained for the HCMV IE-86 early antigen along with an
Alexa-fluor-594 secondary antibody and then counterstained with DAPI. Coverslips were mounted on glass slides and a 0.2 mm section of the Z-stack
(including the central plane of the nucleus) was captured.
doi:10.1371/journal.ppat.1002905.g009
HCMV Entry into Epithelial Cells
PLOS Pathogens | www.plospathogens.org 10 September 2012 | Volume 8 | Issue 9 | e1002905in rates of virus entry (.90%) with a 30-fold increase in PDGFRa.
Human cells can vary in the expression of nectin-1, an HSV
receptor, by 10 fold [64].
Third, the results have potentially important implications for
efforts to infect the numerous cell types that HCMV infects poorly,
especially in the laboratory. HCMV entry into most cells, other
than fibroblasts is poor, e.g. HCMV TR infects only 20–35% of
epithelial and endothelial cells with 10 IU/cell (fibroblast
infectious units), but this can be increased to up to 90% following
PDGFRa transduction. Thus, PDGFRa transduction may mark-
edly benefit studies of both HCMV lab and clinical strains in the
numerous cell types that are difficult to infect.
Materials and Methods
Cells
Human neonatal foreskin fibroblasts (HFF) were obtained from
Invitrogen, and grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Invitrogen) supplemented with 12% fetal bovine serum
(FBS; HyClone). Human retinal pigmented epithelial (ARPE-19)
cells were obtained from ATCC and grown in DMEM/F12 plus
10% FBS. Rat retinal pigmented epithelial cells (rat-RPE), owl
monkey kidney (OMK), and HeLa cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and
grown in Dulbecco’s modified Eagle’s medium (DMEM) (In-
vitrogen) supplemented with 10% fetal bovine serum. ARPE-19
cells that overexpressed human PDGFRa or ARPE-19 cells that
were transduced with a retrovirus expressing an shRNA to
PDGFRa were obtained from Hetian Lei at The Schepens Eye
Research Institute, Harvard Medical School, Boston, MA.
Human umbilical cord vascular endothelial cells (HUVECs) were
a kind gift from Ashley Moses at the Vaccine and Gene Therapy
Institute in Portland, Oregon and were maintained in Medium-
200 plus low serum growth supplement (LSGS) (Invitrogen).
293 M cells were obtained from Microbix Biosystems (Toronto,
Ontario) and were grown in minimal essential medium (MEM,
Invitrogen) plus 10% FBS. Human retinoblastoma cells (911)
were provided by RC Hoeben at the University of Leiden,
Netherlands, and grown in (DMEM) supplemented with 10%
fetal bovine serum. All cells were maintained at 37uCi n5 %C O 2
with the exception of rat-RPE cells which were maintained at
33uCi n5 %C O 2.
Adenovirus vectors
Non-replicating adenovirus vectors expressing PDGFRa and
EGFR, were constructed from plasmid Ad-X-ccdB that was
modified to allow compatibility with the Gateway cloning
technology (Invitrogen). Ad-X-ccdB harbors the adenovirus 5
genome and has a ccdB suicide gene flanked by attP1 and attP2
sites just down stream of the tetracycline induced promoter located
in the E1 coding region. Genes containing compatible attB1 and
attB2 sites can be efficiently recombined into this locus using BP
clonase (Invitrogen). To construct Ad-X-ccdB, a DNA fragment
containing attP1 and attP2 sites and the ccdB gene was isolated
from plasmid pDONR222 (Invitrogen) with the restriction
enzymes HpaI and HindIII and then ligated into the SmaI and
HindIII sites of the shuttle vector pDNR-CMV (Clontech). This
pDNR-CMV shuttle plasmid was then used with the parental
adenovirus plasmid Adeno-X, (Clontech) in a cre-lox reaction
according to the manufacturer’s instructions. The plasmid DNA
was transformed into one-shot ccdB survival cells (Invitrogen) and
bacterial colonies were selected on LB agar plates containing
chloramphenicol and ampicillin. Individual colonies were screened
for the presence of the recombinant adenovirus plasmid contain-
ing the attP sites and the ccdB by extracting and analyzing plasmid
DNA by restriction digestion with BsrGI. A positive clone was
selected and used to construct PDGFRa and EGFR expressing
vectors. To accomplish this, human cDNAs encoding PDGFRa
(Accession # BC0634414) or EGFR (Accession # BC094761) in
plasmid pCMV-SPORT6 (Invitrogen) were purchased from Open
Biosystems. These plasmids were then used for BP-mediated
recombination (Invitrogen) with the Adeno-X-ccdB plasmid
according to the manufacture’s instructions. After in vitro
recombination, the DNA was electroporated into DH10B
electrocompentent cells and recombinant constructs were selected
on LB agar plates containing chloramphenicol and ampicillin.
Individual colonies were screened for the presence of recombinant
adenoviruses by extracting and analyzing plasmid DNA by
restriction digestion with BsrGI. This method was also used to
generate an adenovirus vector expressing human nectin-1 after the
nectin-1 gene was excised from plasmid pBG38 and sub-cloned
into the pCMV-SPORT6 plasmid. The resulting recombinants
termed Ad-X- PDGFRa, Ad-X-EGFR, and Ad-X-Nectin-1 were
then used to generate recombinant viruses. For this, Ad-X-
PDFRA, Ad-X-EGFR DNA, and Ad-X-Nectin-1 DNA was
Figure 10. Models of HCMV entry pathways. A–C). HCMV TR,
AD169 and TB40 are all taken up by dynamin-dependent endocytosis. If
cells are induced to express increased PDGFRa, virus particles can fuse
with endosomes by a low pH-independent mechanism, so that capsids
enter the cytoplasm and can initiate infection after moving to nuclear
pores. Without increased PDGFRa virus particles are degraded,
presumably following delivery to lysosomes. D–F). Wild type HCMV
TR particles which contain gH/gL/UL128–131 can also be taken up by
macropinocytosis into endosomes. There is low pH-dependent fusion
with endosomal membranes delivering capsids into the cytoplasm. It
remains possible that AD169 and TB40 are also taken up by
macropinocytosis but cannot exit endosomes derived from this process.
doi:10.1371/journal.ppat.1002905.g010
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with PacI (New England Biolabs) to linearize the adenovirus DNA,
and then transfected into 911 retinoblastoma cells by calcium
phosphate transfection. Cells were monitored for 4–6 days for the
presence of adenovirus induced CPE, at which point total cell
lysates containing infectious adenovirus were generated by
harvesting cells and lysing by sonication. Cell lysates were stored
at 280uC until future use. Adenovirus vectors expressing the
tetracycline transactivator (Ad-tet-trans), HCMV gB, gH, gL,
UL128, UL130, UL131, and HSV-1 gB, gH, gL, and gD were
constructed as described previously [12,38] All large scale
adenovirus vector stocks were generated by infecting 293 M cells
(Microbix) at 0.1 plaque forming unit (PFU)/cell. Cells were
harvested 6–10 days after infection and centrifuged at 8006g for
5 min. Cell pellets were suspended in DMEM plus 10% FBS,
sonicated to release cell-associated virus, followed by centrifuga-
tion at 30006g for 5 min to remove large cellular debris. Virus-
containing cell lysates were stored at 280uC. Ad stock titers were
determined by plaque assays on 293 M cells.
HCMV
HCMV TR is a clinical HCMV strain that was derived from an
ocular vitreous fluid sample from a patient with HIV disease and
was cloned into a BAC after limited passage in fibroblasts [65,66].
The HCMV strain AD169 was provided by Jay Nelson at the
Vaccine and Gene Therapy Institute in Portland, Oregon.
Construction of TR D4 and TR D131 has been described
previously [9]. HCMV VR-1578 derived from TB40/E and
expressing a fluorescent tegument protein (pp150-EGFP) [56] was
obtained from the American Type Culture Collection. HCMV
stocks were produced from HFF cells grown in roller bottles and
viral particles were purified and concentrated from culture
supernatants by centrifugation through a cushion of 20% sorbitol
in PBS at 50,0006g for 1 h. Pellets were resuspended in DMEM
plus 10% FBS and frozen at 270uC. Stocks were titered by
determining the number of infectious units per ml (IU/ml) by
plating serial dilutions of virus preparations on HFF cells and
staining for IE-86 after 24 hr as described below.
Reagents and antibodies
The chemical inhibitors Dynasore hydrate, Chlorpromazine
hydrochloride, Rottlerin, and 5-(N-Ethyl-N-isopropyl) amiloride
(EIPA) were obtained from Sigma-Aldrich. Imantinib Methane-
sulfonate (Gleevec) was obtained from LC laboratories (Wood-
burn, MA). The MAb clone LA1 (neutralizing) to EGFR and the
rabbit anti-phospho-PDGFRa (Tyr-742) antibody was obtained
from Millipore (Temecula, CA). The rabbit polyclonal antibody
61219 to PDGFRa was obtained from Abcam (Cambridge, MA).
Human recombinant platelet-derived growth factor (PDGF-AA)
and the mouse MAbs 35248 (neutralizing) and PRa292 as well as
the polyclonal antibody AF-307-NA (neutralizing) to PDGFRa
was obtained from R & D Systems (Minneapolis, MN). The MAb
16A1 to PDGFRa was obtained from NOVUS biologicals
(Littleton, CO). The polyclonal antibody 31614 used in western
blots to detect PDGFRa was obtained from cell signaling
technology, (Danvers, MA). The rabbit polyclonal antibody
R638 to HCMV IE-86 [67] was a kind gift of Jay Nelson
(O.H.S.U.) and the mouse MAb 58S to HSV-1 ICP4 [68] was a
gift of Roger Everett (University of Glasgow).
Immunofluorescence staining
To stain for specific antigens, cells were fixed with PBS
containing 2% formaldehyde for 10 min at room temperature
then permeabilized with immunofluorescence (IF) buffer (PBS
supplemented with 0.5% Triton X-100, 0.5% deoxycholate, 2%
goat serum, and 0.05% sodium azide) for 30 min before
incubation with primary antibodies diluted in IF buffer for 1 h.
To detect PDGFRa and EGFR expression, cells were stained with
the polyclonal AF-307-NA or MAb LA1, respectively. To detect
HCMV or HSV-1 infected cells, cell monolayers were stained with
the primary antibodies R638 or 58S that recognize the HCMV
IE-86 and HSV-1 ICP4, respectively. After primary antibody
incubation, cells were then washed several times with IF buffer and
stained with a Dylight 594-goat anti-mouse, Dylight 594-goat anti-
rabbit, or FITC-conjugated donkey anti-goat secondary antibodies
in IF buffer for 1 h. The nuclei were then counterstained by
incubating the cells in PBS containing DAPI (49,6-diamidino-2-
phenylindole) for 20 min and then the glass coverslips were
mounted on glass slides with fluoromount-G (SouthernBiotech).
Immunofluorescence microscopy was performed on a Nikon TE
200-based Applied Precision Instruments (API) Deltavision image
restoration system.
HCMV entry assays
Cell monolayers seeded in 24-well culture dishes were
transduced with Ad vectors for 24 hr then infected with purified
HCMV using 10 IU/cell (1 IU/cell for fibroblasts) in DMEM
containing 2% FBS at 376C for 4 h. After 4 hr, the cells were
washed once with PBS to remove the virus inoculum and then
incubated in growth media (DMEM containing 10% FBS) for
24 hr. For PDGF-AA ligand competition assays, cells were pre-
incubated in infection media containing PDGF ligand at 46C for
30 min then HCMV virions added at 10 IU/cell for an additional
30 min at 46C. The cells were then incubated at 376C for 4 hr,
the virus inoculum was removed, the cells washed once with PBS,
and incubated in fresh growth media containing the same
concentration of ligand at 376C with for 24 hr. For antibody
inhibition assays, cells in media containing 2% FBS and various
concentrations of PDGFRa-specific antibodies were incubated at
46C for 1 hr then HCMV virions at 10 IU/cell added for 4 hr at
376C. The cells were then washed once with PBS and incubated
in fresh media containing 10% FBS and the same concentration of
PDGFRa-specific antibodies at 376C for 24 hr. For infection
assays performed in the presence of drugs or chemical inhibitors,
cells were pre-incubated in media containing 2% FBS and
chemical inhibitors or drugs for 1 hr at 376C then infected with
purified HCMV virions using 10 IU/cell at 376C for 4 h in the
presence of drugs. The virus inoculum was removed, the cells
washed once with PBS, then fresh media containing 10% FBS and
the same concentration of drugs or inhibitors. To monitor for drug
or chemical induced cytotoxicity (postinfection), cells were infected
with HCMV for 4 hr to allow virus entry then drugs or chemicals
were then added for 24 h. At the end of these 24 hr infections,
HCMV IE-86 was measured by immunofluorescence as described
above.
Internalization and nuclear transport of UL32-EGFP-
HCMV
Entry assays involving UL32-EGFP-HCMV were performed
using ARPE-19 cells seeded on glass coverslips. Cells were
incubated with UL32-EGFP-HCMV supernatant stock using 10
IU/cell for 1 hr. The cells were washed once with PBS and
allowed to continue to incubate in fresh media containing 10%
FBS for 4,6, 8, and 12 h then the cells were fixed with PBS
containing 4% paraformaldehyde, counterstained with DAPI,
mounted on glass slides, and analyzed as by immunofluorescence
microscopy as described above.
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ARPE-19 cells seeded on glass coverslips were treated with
30 uM chlorpromazine in serum-free media at 376C for 1 hr. The
media was then replaced with fresh serum-free media containing
0.1 mg/ml of Alexa-fluor-488 conjugated transferrin (Invitrogen)
and the cells were incubated at 376C for 30 min. The cells were
then placed on ice, washed once with citrate buffer (40 mM citric
acid, 10 mM KCl, 135 mM NaCl, pH 3.0) and then fixed with
PBS containing 4% paraformaldehyde and nuclei counterstained
with DAPI then cells characterized by immunofluorescence
microscopy as described above.
Interference assays
ARPE-19 epithelial cells seeded in 24-well culture dishes were
transduced with non-replicating Ad vectors expressing tet-trans,
the HCMV glycoproteins gH/gL/UL128-131 or PDGFRa. Tet-
trans and the HCMV glycoprotein expressing Ad vectors and the
Ad-PDGFRa vector were used at 50 PFU/cell. For conditions in
which cells expressed tet-trans, PDGFRa or the gH/L/UL128-
131 alone, an Ad vector expressing GFP (Ad-GFP) was added at
different amounts so that the total number of PFUs for ARPE-19
cells was 350. The cells were allowed to incubate for 24 h to allow
for adequate protein expression and then infected with HCMV
TR at 10 IU/cell. At 24 h after infection with HCMV, entry was
analyzed by immunofluorescence staining for HCMV IE-86 as
described above.
Cell-cell fusion assays
Target and effector cells were generated by transducing cells
with Ad vectors at 50 PFU/cell. At 16 h post-transduction, the
cells were washed thoroughly with PBS and trypsinized with
0.025% trypsin/EDTA buffer. After the cells were released from
the dish, the cells were counted and an equal number of target and
effector cells were mixed and re-plated onto culture dishes and
maintained in growth media for an additional 24-36 h. To assess
the level of fusion, cells were fixed in PBS containing 2%
formaldehyde, permeabilized with PBS containing 0.2% triton X-
100, and stained with a 5 um stock of SYTO 13 green fluorescent
nucleic acid stain (Invitrogen) diluted 1:20,000 in PBS. Images
were captured on Nikon eclipse TS100 microscope fitted with a
Qiacam digital CCD camera and the level of fusion was quantified
by counting the total number of cell nuclei involved in syncytia
formation divided by the total number of nuclei in the same field
and expressed as the percentage of cells fused.
Radiolabeling cells and immunoprecipitation
Cells were labeled with with [
35S]-methionine/cysteine by first
washing in medium lacking methionine and cysteine followed by
incubation in this media for 30 min at 37u C. The cells were then
incubated in labeling medium supplemented with [
35S]-methio-
nine/cysteine (300 mCi/ml; Amersham) for 4 h at 37u C. Extracts
of labeled cells were made using 1% NP40 in PBS supplemented
with 1 mg/ml bovine serum albumin and 1 mM phenylmethyl-
sulfonyl fluoride. Extracts were then precleared by incubation with
protein A-agarose beads for 30 min and then the protein A-
agarose removed by low speed centrifugation. To immunoprecip-
itate labeled proteins, 200 ng of anti-PDGFRa AF-307-NA or
anti-EGFR LA1 were added to the clarified lysates to immuno-
precipitate PDGFRa and EGFR, respectively. Lysates were
incubated with antibodies for 2 h followed by protein A-agarose
(50 ml) for an additional 2 h. The agarose beads were centrifuged
at low speed, washed three times in 1% Triton X-100 in PBS, and
eluted from the protein A-agarose by boiling for 5 min in 26SDS
loading buffer (100 mM Tris-Cl pH6.8, 20% glycerol, 4% SDS,
4% b-mercaptoethanol, 0.02% bromophenol blue) and separated
by electrophoresis using 10% SDS-polyacrylamide gel.
SDS-PAGE and Western blotting
ARPE-19 cell extracts were prepared by scraping cells into 1 ml
PBS, centrifuging the cells at 8006g for 2 min and then lysing the
cell pellet in 30 ul of protein extraction buffer (10 mM Tris-HCl
pH 7.4, 5 mM EDTA, 50 mM NaCl, 1% triton X-100, 1 mM
phenylmethylsulfonyl fluoride) and then centrifuged for 5 min at
13,0006g. The supernatant was removed and diluted in 26SDS
loading buffer and boiled for 5 min. A portion of the sample equal
to 3610
5 cells was loaded into a single lane of a 10% SDS-
polyacrylamide gel and separated by electrophoresis. Proteins
were electrophoretically transferred to Immobilon membranes
(Millipore) in a buffer containing 25 mM Tris, 192 mM glycine,
and 20% methanol. Membranes were blocked in TBST (Tris-
buffered saline with 0.1% tween-20 and 5% bovine serum
albumin) for 30 min and then incubated TBST containing anti-
PDGFRa 31614 or anti- b-actin (Sigma) diluted 1:1000 and
allowed to incubate at 46C overnight. The blots were then washed
three times with TBST and then incubated for 1 h in TBST with a
1:1000 dilution of horseradish peroxidase-conjugated goat anti-
mouse or mouse anti-rabbit IgG (Amersham). The blots were
washed with TBST and proteins were visualized by incubating
membranes in ECL chemiluminescent detection reagent (Pierce)
for 60 sec and then exposing the membranes in an ImageQuant
LAS 4000 detections system (General Electric).
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